Alpha9 Theranostics is a biopharmaceutical company founded in 2019 and headquartered in Vancouver, Canada. The company is dedicated to developing radiotherapeutics for treating both solid and hematologic cancers, harnessing the power of radiotherapeutics for innovative cancer treatment solutions. Alpha9 Theranostics is establishing a robust lineup of radiopharmaceuticals to address these malignancies, and its methodical approach to designing radiotherapeutics is driven by a toolkit of various technologies and chemistries, providing significant opportunities for expansion into diverse oncology targets.
The most recent investment in Alpha9 Theranostics was a $75.00M Series B investment on 14 December 2022. The investors in this round included Longitude Capital, GHS Fund, Nextech Invest, Samsara BioCapital, Frazier Life Sciences, and Biotechnology Value Fund.
As a company focused on biotechnology, Alpha9 Theranostics presents an attractive opportunity for investors looking to support the development of innovative cancer treatment solutions with the potential for significant impact in the field of oncology.
